(Q36984895)

17 August 2017

1 reference

title

Therapy insight: how the gut talks to the joints--inflammatory bowel disease and the spondyloarthropathies (English)

1 reference

inflammatory bowel diseases

17 August 2017

1 reference

Carmen Meier

1

1 reference

PubMed ID

17968338

17 August 2017

Scott Plevy

series ordinal

2

1 reference

17 August 2017

1 November 2007

1 reference

Nature Clinical Practice Rheumatology

17 August 2017

1 reference

17 August 2017

3

1 reference

17 August 2017

667-674

1 reference

17 August 2017

11

1 reference

Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease

17 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

THE EXTRA-INTESTINAL COMPLICATIONS OF CROHNʼS DISEASE AND ULCERATIVE COLITIS: A STUDY OF 700 PATIENTS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Inflammatory bowel disease genetics: Nod2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Course of gut inflammation in spondylarthropathies and therapeutic consequences

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

High frequency of silent inflammatory bowel disease in spondylarthropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Jejuno-ileal bypass arthropathy: its clinical features and associations

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

pANCA represents a cross-reactivity to enteric bacterial antigens

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Inflammatory bowel disease-specific autoantibodies in HLA-B27-associated spondyloarthropathies: increased prevalence of ASCA and pANCA

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Role ofNOD2 variants in spondylarthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Clinical investigation of methotrexate in the treatment of ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Methotrexate for ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Seronegative arthritis and the bowel

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Ileal pouchitis and arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

The importance of ileocaecal integrity in the arthritic complications of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0625

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0625

1 reference

17 August 2017

1 reference

PubMed ID

17968338